Media

Lundbeck seeks an open and active dialogue with the press. Members of the press are always welcome to direct enquiries to our press contacts who work to serve members of the press quickly and professionally.

We are a global pharmaceutical company engaged in the research and development, production, marketing, sale and distribution of drugs for the treatment of brain disorders such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington's disease, epilepsy and insomnia.

Lundbeck is among the companies which have the largest research spend as a percentage of revenue. In total we employ more than 1,200 highly qualified and specialised employees in our research and development departments.

Every year Lundbeck invests more than 20 percent of its revenue in the research and development of new innovative drugs, which will improve the treatment of the millions of people suffering from brain disorders all over the world.

In total Lundbeck, headquartered in Copenhagen, Denmark, employs more than 5,900 people all over the world, 2,100 of which work in Denmark. Lundbeck has employees in 56 countries and our products are approved and registered in more than 100 countries. In 2009 Lundbeck’s revenue amounted to DKK 13,7 billion.

Get a quick company overview